Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/13/2003US20030211171 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
11/13/2003US20030211170 Wound healing agents
11/13/2003US20030211166 Stabilized hyaluronic acid; injectable; drug delivery
11/13/2003US20030211165 Anticancer agents; mixture of hydrophilic, crosslinked polymer and drugs
11/13/2003US20030211164 Method for preparing microparticles having a selected polymer molecular weight
11/13/2003US20030211163 Combination antiviral therapy
11/13/2003US20030211162 Heating with carrier; mixtur eof fine and coarse particle sizes
11/13/2003US20030211161 Anhydrous mixture of polyalcohol and insulation gel; dysmenorrhea
11/13/2003US20030211160 Pharmaceutical compositions
11/13/2003US20030211159 Gaseous extraction of solvent
11/13/2003US20030211158 Microgel particles for the delivery of bioactive materials
11/13/2003US20030211157 Fineness particle sizes; therapy for drug abruse; sustained release; dispersed in biopolymer
11/13/2003US20030211156 Film-coated tablet for improved upper gastrointestinal tract safety
11/13/2003US20030211155 Stabilized pharmaceutical composition
11/13/2003US20030211153 Somatotropin in biocompatible polymer matrix; aqueous solution administering by injection
11/13/2003US20030211152 Controlled release formulation for treating COPD
11/13/2003US20030211150 Immediate release tablet containing naproxen sodium
11/13/2003US20030211149 Extended release tablets comprising felodipine
11/13/2003US20030211148 Neutralization mixtures; spraying
11/13/2003US20030211145 Antiinflammatory agents, analgesics, antiarthritic agents; liquid filled capsulaes
11/13/2003US20030211144 Water-insoluble drug delivery system
11/13/2003US20030211143 Emulsion and micellar formulations for the delivery of biologically active substances to cells
11/13/2003US20030211140 Lipid encapsulating hydrophobic core; drugs; anesthetic
11/13/2003US20030211138 Reversable heat sensitive element; heat patch; skin disorders
11/13/2003US20030211136 Mixture of water soluble polymer, taste masking compound and drug
11/13/2003US20030211134 Topical glycopyrrolate product
11/13/2003US20030211133 Mixture of methylcobalamin and vitamin b
11/13/2003US20030211126 Composition for topically delivering vitamin c
11/13/2003US20030211123 Using citric acid esters or ethers
11/13/2003US20030211113 Administering immunosuppressant
11/13/2003US20030211101 Vascular endothelial growth factor-like protein from ORF viruses binds and activates mammalian VEGF receptor-2, and uses thereof
11/13/2003US20030211100 Gene therapy; nucleic acid coding immunoglobulins; anticancer agents
11/13/2003US20030211092 Genetic engineering; gene expression; culture product
11/13/2003US20030211091 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/13/2003US20030211079 Immobilization with polyoxyethylene glycol; adjust circulation half-life
11/13/2003US20030211077 Stimulanting hematopoiesis
11/13/2003US20030211074 Synergistic mixture of polyacrolein and isothiazolin-3-one compounds
11/13/2003US20030211072 Compositions with enhanced oral bioavailability
11/13/2003US20030211071 Containing crosslinked polymer and active material
11/13/2003US20030211066 Stable hydroalcoholic compositions
11/13/2003US20030211065 Alopecia; mutant gene
11/13/2003US20030211047 High speed absorption; mixture of aqueous polar solvent, propellant, active material and flavor
11/13/2003US20030211046 Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer
11/13/2003US20030211043 Staining tear film with dye; monitoring, calibration
11/13/2003US20030211039 Method of diagnosing, monitoring, staging, imaging and treating colon cancer
11/13/2003US20030209243 Dry powder dispersing apparatus and methods for their use
11/13/2003US20030209210 Animal brushes
11/13/2003CA2787384A1 Polymeric adhesive transdermal patch comprising rotigotine for treatment of restless leg syndrome
11/13/2003CA2753371A1 Heterocyclic derivatives as opioid receptor modulators
11/13/2003CA2749172A1 Re-epithelializing pharmaceutical compositions comprising xanthan gum
11/13/2003CA2736019A1 Methods and compositions for treating ectoparasite infestation
11/13/2003CA2703698A1 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003CA2524569A1 A method of regulating gene expression
11/13/2003CA2500134A1 Methods of simultaneously treating mucositis and fungal infection
11/13/2003CA2491708A1 Non-viral gene delivery system
11/13/2003CA2487693A1 Method for producing preparations rich in tocotrienol
11/13/2003CA2485116A1 Use of epa and dha in secondary prevention
11/13/2003CA2485115A1 The treatment of pain with ifenprodil
11/13/2003CA2485110A1 Expression system for large functional proteins
11/13/2003CA2485093A1 Substituted imidazole derivatives: gabaa receptor ligands
11/13/2003CA2485086A1 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes
11/13/2003CA2485065A1 Semicarbazide derivatives for combating thromboembolic diseases
11/13/2003CA2484983A1 5-ethyl-imidazo (5,1-f) (1,2,4,) triazin-4 (3h) -ones as phosphodiesterase inhibitors
11/13/2003CA2484976A1 Method of inhibiting angiogenesis
11/13/2003CA2484963A1 7-hydroxy-16a-fluoro-5-androsten-17-ones and 7-hydroxy-16a-fluoro-5-androstan-17-ones and derivatives thereof
11/13/2003CA2484959A1 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
11/13/2003CA2484921A1 Nucleoside derivatives for treating hepatitis c virus infection
11/13/2003CA2484874A1 Monocompartment osmotic controlled drug delivery system
11/13/2003CA2484797A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
11/13/2003CA2484624A1 Carvedilol pharmasolve solvate
11/13/2003CA2484621A1 Carvedilol formulations
11/13/2003CA2484600A1 Therapeutic use of selective pde10 inhibitors
11/13/2003CA2484599A1 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003CA2484597A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors
11/13/2003CA2484582A1 Bombesin antagonists
11/13/2003CA2484425A1 Fusions of cytokines and tumor targeting proteins
11/13/2003CA2484334A1 High-quality lipids and methods for producing by enzymatic liberation from biomass
11/13/2003CA2484329A1 Warming and nonirritating anhydrous lubricant compositions
11/13/2003CA2484318A1 Warming and nonirritating lubricant antifungal gel compositions
11/13/2003CA2484312A1 Catechin multimers as therapeutic drug delivery agents
11/13/2003CA2484303A1 Salt solution for colon cleansing
11/13/2003CA2484258A1 Soya cell strains with high isoflavone content
11/13/2003CA2484209A1 Protein kinase modulators and methods of use
11/13/2003CA2484189A1 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003CA2484173A1 4-azasteroid derivatives as androgen receptor modulators
11/13/2003CA2484162A1 Imidazo-triazine derivatives as ligands for gaba receptors
11/13/2003CA2484095A1 Tricyclic macrolide antibacterial compounds
11/13/2003CA2484087A1 Antibacterial compounds with improved pharmacokinetic profiles
11/13/2003CA2484065A1 Inhibitors of histone deacetylase
11/13/2003CA2483996A1 Promoters exhibiting endothelial cell specificity and methods of using same
11/13/2003CA2483929A1 A method for inhibiting platelet aggregation
11/13/2003CA2483927A1 Treatment of diabetes and diabetic complications with nhe-1 inhibitors
11/13/2003CA2483917A1 Formulations limiting spread of pulmonary infections
11/13/2003CA2483904A1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-[1,2,4]-triazole for the treatment of autoimmune diseases
11/13/2003CA2483865A1 7-aminoimidazotriazones
11/13/2003CA2483857A1 Use of dimesna for mitigating taxane induced neurotoxicity
11/13/2003CA2483846A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003CA2483843A1 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
11/13/2003CA2483838A1 Chemically activated carboxypolysaccharides and uses
11/13/2003CA2483830A1 Process for preparing highly functionalized y-butyrolactams and y-amino acids
1 ... 5278 5279 5280 5281 5282 5283 5284 5285 5286 5287 5288 5289 5290 5291 5292 5293 5294 5295 5296 5297 5298 ... 7860